Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Keurig Dr Pepper has staged a sharp 9% rally this week, and the shorts are running for the exits ahead of a Q3 earnings print and a pending coffee business spinoff that reshapes the investment case entirely.
Short sellers have cut positions aggressively. Short interest as a percentage of the free float dropped 10.2% over the week to 5.28% of float, one of the more decisive week-on-week reductions in the past six weeks. The retreat erases a build that peaked in late September, when shorts were running above 91 million shares and the stock was trading lower. Borrowing costs have eased in tandem, now at 0.43%, down 11% on the week, and availability in the lending pool remains very loose at 805%, meaning there are roughly eight shares available for every one currently borrowed. Nothing in the borrow market suggests the short community is preparing a fresh offensive; if anything, the lend is widening as shorts cover.
Options positioning adds nuance but not alarm. The put/call ratio is 0.36, modestly above its 20-day average of 0.33 but well within a standard deviation of normal. The reading sits near the middle of the past year's range (52-week low 0.27, high 0.81), which points to neither heavy hedging nor speculative call-chasing. The ORTEX short score is 48.1, drifting slightly lower over the past ten days, consistent with a stock where bearish pressure is fading rather than building.
The Street's view has been a tailwind all summer. After JP Morgan raised its target from $33 to $38 in late July, UBS followed with a lift to $39, Barclays moved to Overweight and raised to $38, and HSBC upgraded to Buy in mid-August with a $40 target. The analyst consensus is "hold," reflecting a handful of more cautious voices alongside the bullish cluster, but the direction of revisions since Q2 results has been consistently upward. The mean target of $36.21 is now below the current price of $34.62, though several individual targets run well above that level. Bulls point to improving US coffee and ready-to-drink retail sales momentum and the prospect that deleveraging accelerates once the coffee spinoff closes. Bears note that pro-forma leverage remains elevated at roughly 5.2x and that brewer shipments fell about 25% in Q3 2025. The P/E multiple has expanded by about 1.4 points over the past 30 days to 13.9x, tracking the stock's re-rating, while EV/EBITDA has compressed modestly, now at 8.7x. The dividend factor score ranks in the 89th percentile, one of the stronger readings in the beverage peer group.
The spinoff itself deserves attention as a structural angle. ORTEX puts the probability at 60% that index trackers will see a share-count decrease in the Russell 1000, Russell 3000, Nasdaq-100 and S&P 500 following the separation of the Global Coffee business from the remaining Dr Pepper and beverage portfolio. The indicative trade date for index adjustments is around March 30, 2027, with an estimated effective date of March 31, though those dates are unconfirmed and the event is classified as a forecast, not an announcement. There is no immediate mechanical flow from tracker funds, but the pending separation is already changing how investors frame the stub valuation, and it is a cleaner beverage-only business that most of the bullish analyst upgrades are implicitly pricing.
On the ownership side, the activist register carries one item worth flagging. JAB BevCo B.V. filed a 13D/A in May 2025 showing a stake reduced from 9.9% to 4.4% of the class, falling below the 5% threshold. As with all 13D/G disclosures, the position is "as last disclosed" and the holder could have moved further without filing again. The broader institutional base is stable: Capital Research, BlackRock and FMR are each holding above 10% per their latest filings through September 30.
Q3 results are due on November 3. After the last two prints the stock fell roughly 2.4% on the day before recovering to modest gains within the following week, a pattern that limits the base case for a dramatic post-earnings re-rating in either direction. What to watch is whether management updates its leverage trajectory and gives any timeline certainty on the coffee separation, both of which have driven more analyst activity this cycle than the top-line numbers alone.
See the live data behind this article on ORTEX.
Open KDP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
